NIP142

NIP142 is an orally bioavailable, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed by China Pharmaceutical Research and Development Center. It is designed to selectively and irreversibly inhibit EGFR-sensitizing mutations, such as L858R and exon 19 deletions, as well as the T790M resistance mutation. By targeting these specific mutations while sparing wild-type EGFR, NIP142 aims to provide therapeutic efficacy in non-small cell lung cancer (NSCLC) patients with reduced off-target toxicities like skin rash and diarrhea. It is currently undergoing clinical evaluation for advanced NSCLC in patients who have developed resistance to earlier-generation TKIs.